UPMC Hillman Cancer Center ASCO 2023 Presentations

Friday, June 2


Divya Natesan
“Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network”
8 to 11 a.m.
Hall A | Abstract 2592 | Board 434

Jingxiao Jin, MD
“Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.”
1:15 to 4:15 p.m.
Abstract 9540 | Board 303

Andrew David Knight, MD
“Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.”
1:15 to 4:15 p.m.
Abstract 9580 | Board 343

Lewis Wu, MD
“A radiomic-based predictive model of lung adenocarcinoma brain metastases and molecular subtypes.”
1:15 to 4:15 p.m.
Discussion S504 | Abstract 2014| Board 371

Saturday, June 3


Phoung Mai, MD – Chair and Abstract
“Prevention, Risk Reduction, and Hereditary Cancer”
4:30 to 6 p.m.

Annie Im, MD – Chair
Emily MacDuffie, MD – Abstract
“No One Left Behind: Enhancing Equity in Oncology/ABSTRACT – The ticking “biological clock”: Reproductive assistance, costs, and elective fertility preservation in female oncologists and trainees.”
4:30 to 6 p.m.

Monday, June 5


Robert Ferris, MD, PhD
“Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.”
1:15 to 4:15 p.m.
Hall A | Abstract 6035 | Board 28


Benjamin Nacev, MD, PhD
“Integrating Genomic Profiling in the Care of Patients with Sarcoma from Diagnosis to Therapy”
3 to 3:20 p.m.

Jason J. Luke, MD, FACP
“Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.”
4:24 p.m.
Hall D | Abstract LBA9505

Heath Skinner, MD, PhD
“Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.”
4:30 to 4:42 p.m.
E451 Poster Discussion | Abstract 6014

Access PDF version of presenter list here.

Tagged with: